ERBB2 and ductal breast carcinoma in situ: DC vaccines have been shown to prime an immune response in vaccinated subjects and, in one study, has achieved pCR in 18% of subjects and eradication of HER2 expression in residual DCIS in 50% of subjects without pCR (173).